Bicara therapeutics announces upcoming presentations at aacr annual meeting 2025

Boston, march 25, 2025 (globe newswire) -- bicara therapeutics inc. (nasdaq: bcax), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the american association for cancer research (aacr) annual meeting 2025, which will be held from april 25-30, 2025 in chicago, il. ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (egfr) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (tgf-Β) and is being evaluated across multiple solid tumor types.
BCAX Ratings Summary
BCAX Quant Ranking